Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression

Human Psychopharmacology

Volumn 11, Issue 4, 1996, Pages 293-298

  Ansseau, Marc ^a   Bataille, Michel ^b   Briole, Guy ^c   De Nayer, André ^d   Fauchère, Pierre André ^e   Ferrero, François ^f   Mertens, Claudine ^g   Realini, Renzo ^e   Rombaut, Philippe ^h   Vereecken, André ^h   Troisfontaines, Benoît ⁱ   Van Moffaert, Myriam ^j  

^a CHU SART TILMAN   (Belgium)

^b Clinique Notre Dame   (Belgium)

^c Hôpital des Armées Val de Grace   (France)

^d Clin Sainte Thérèse   (Belgium)

^e Policlinique Psychiat Univ B ^*

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g Psychiatrische Centra Sleidinge   (Switzerland)

^h Psychiatrisch Ziekenhuis Sint Jan   (Belgium)

ⁱ Clinique St Vincent   (Belgium)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Adjustment disorders; Alprazolam; Antidepressant drugs; Mianserin; Mixed anxiety depressive disorder; Tianeptine

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MIANSERIN; PLACEBO; PSYCHOTROPIC AGENT; TIANEPTINE;

ADULT; ANXIETY NEUROSIS; APPETITE DISORDER; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALADJUSTMENT; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SOMNOLENCE; STRESS; VERTIGO;

EID: 9344258635     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199607)11:4<293::AID-HUP771>3.0.CO;2-Z     Document Type: Article

References (25)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn revised, (DSM-III-R). American Psychiatric Press, Washington, DC.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. American Psychiatric Press, Washington, DC.
3. Ansseau, M. (1993). The paradox of tianeptine. European Psychiatry, 8 (Suppl. 2), 89s-93s.
4. Bobon, D., Baumann, U., Angst, J., Helmchen, H. and Hippius, H. (Eds) (1983). The AMDP-System in Pharmacopsychiatry. Karger, Basel.
5. Brogden, R. N., Heel, R., Speight, T. M. and Avery, G. S. (1978). Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs, 16, 273-301.
6. Broqua, P., Baudrie, V., Laude, D. and Chaouloff, F. (1992). Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats. Biological Psychiatry, 31, 391-400.
7. Covi, L., Lipman, R., McNair, D. M. and Czerlinski, T. (1979). Symptomatic volunteers in multicenter drug trials. Progress in Neuropsychopharmacology, 3, 521-533.
8. CPMP Working Party on Efficacy of Medicinal Products (1990). EEC Note for Guidance: Good clinical practice for trials on medicinal products in the European Community. Pharmacology and Toxicology, 67, 361-372.
9. Delbende, C., Contesse, V. and Mocaër, E. (1991). The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. European Journal of Pharmacology, 202, 391-396.
10. Fomanges, R., Mimouni, J., de Grieve, X., Picard, J., Pugeat, M. and Bange, C. (1993). Effect of tianeptine on neuroendocrine, enzyme and behavioral responses to restraint stress in male rats. European Psychiatry, 8 (Suppl. 2), 67s-73s.
11. Guelfi, J. D., Pichot, P. and Dreyfus, J. F. (1989). Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology, 22, 41-48.
12. Guy, W. (Ed.) (1976). ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD.
13. Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.
14. Jonas, J. M. and Cohon, M. S. (1993). A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Journal of Clinical Psychiatry, 54 (Suppl.) 25-45.
15. Kaplan, H. I. and Sadock, B. J. (Eds) (1990). Pocket Handbook of Clinical Psychiatry. Williams and Wilkins, Baltimore.
16. Mathieu, M. (1990). New Drug Development: a Regulatory Overview. Parexel, Cambridge, MA.
17. McEwen, B. S., Angulo, J., Gould, E., Mendelson, S. and Watanabe, Y. (1993). Antidepressant modulation of isolation and restraint stress effects on brain chemistry and morphology. European Psychiatry, 8 (Suppl. 2), 41s-48s.
18. Montgomery, M. and Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
19. Raskin, A., Schulterbrandt, J., Reatig, N. and Rice, C. E. (1967). Factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressions. Journal of Consulting Psychology, 31, 270-278.
20. Samuelian, J. C., Chariot, V., Derynck, F., Rouillon, F. and G. E. P. (1994). Troubles de l'adaptation: à propos d'une enquête épidémiologique. Encéphale, 20, 755-765.
21. Stein, M. B., Kirk, P., Prabhu, V., Grott, M. and Terepa, M. (1995). Mixed anxiety-depression in a primary-care clinic. Journal of Affective Disorders, 34, 79-84.
22. Wilde, M. I. and Benfield, P. (1995). Tianeptine: review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs, 49, 411-439.
23. Wittchen, H. U. and Essau, C. A. (1993). Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Journal of Clinical Psychiatry, 54 (Suppl. 1), 9-15.
24. World Health Organization (1992). International Classification of Diseases, 10th edn. American Psychiatric Press, Washington, DC.
25. Zajecka, J. M. and Ross, J. S. (1995). Management of comorbid anxiety and depression. Journal of Clinical Psychiatry, 56 (Suppl. 2), 10-13.